Lewy body Dementia - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lewy body Dementia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Lewy body Dementia - Pipeline Review, H2 2016', provides an overview of the Lewy body Dementia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia
- The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects
- The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Lewy body Dementia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lewy body Dementia Overview 6
Therapeutics Development 7
Pipeline Products for Lewy body Dementia - Overview 7
Lewy body Dementia - Therapeutics under Development by Companies 8
Lewy body Dementia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Lewy body Dementia - Products under Development by Companies 12
Lewy body Dementia - Companies Involved in Therapeutics Development 13
Axovant Sciences Ltd. 13
BioArctic AB 14
Eisai Co., Ltd. 15
Immungenetics AG 16
Sumitomo Dainippon Pharma Co., Ltd. 17
Takeda Pharmaceutical Company Limited 18
Lewy body Dementia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
(donepezil hydrochloride + glycopyrrolate) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(glycopyrrolate + rivastigmine) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BAN-0805 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
E-2027 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
intepirdine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
nelotanserin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
TAK-071 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
TAK-915 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
zonisamide - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Lewy body Dementia - Dormant Projects 42
Lewy body Dementia - Product Development Milestones 43
Featured News & Press Releases 43
Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia 43
Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia 44
Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Lewy body Dementia, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H2 2016 13
Lewy body Dementia - Pipeline by BioArctic AB, H2 2016 14
Lewy body Dementia - Pipeline by Eisai Co., Ltd., H2 2016 15
Lewy body Dementia - Pipeline by Immungenetics AG, H2 2016 16
Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 17
Lewy body Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Assessment by Combination Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Lewy body Dementia - Dormant Projects, H2 2016 42